T H E   N I H    C A T A L Y S T N O V E M B E R   -   D E C E M B E R   1 9 9 7

IN ADDITION...

 

INTEREST GROUP GAZETTE

Therapeutic Oligonucleotides Interest Group

The second NIH symposium on Therapeutic Oligonucleotides will be held Friday, December 5, 1997, from 8:30 a.m. to 5:30 p.m. in Masur Auditorium (at the Clinical Center.) and will address "Targeting Transcription Factors and Signaling Pathways." For further information, contact:

Yoon Sang Cho-Chung
Head, Therapeutic Oligonucleotides Interest Group, NCI
Tel: (301) 496-4020
FAX: (301) 496-2443
Email: <yc12b@nih.gov>

Cornea Interest Group

They can't go on meeting like this, so after a year of meetings without benefit of official status, the Cornea Interest Group has formally organized as such. The group exchanges ideas on a variety of topics related to the ocular cornea, reviews papers in the field, and discusses current experimental findings, problems, and technical developments. Members are clinical and basic researchers from NIH and from local universities.
Meeting Time: first Monday of each month, 9:00-10:00 am
Meeting Place: Building 6, Room 412
Contact: Christina Sax
Phone: 402-4342
E-mail: <sax@helix.nih.gov>

Birth Defects and Teratology Interest Group

Contrary to information in the otherwise flawless Interinstitute Interest Group Directory pullout in the July-August Catalyst, the telephone number for contact person Dorothea de Zafra, of NIAAA, is 443-6516.

The interest group's web site is <http://www.nih.gov/sigs/birth-def/>.

Social Structure and Demographic Issues in Health Interest Group

The new e-mail address for contact person Laura Montgomery, NCHS/CDC, is <lem3@cdc.gov>.

In Vivo NMR Interest Group

The name of this new interest group was established at a September founding meeting, at which it was also decided that the group would be open to all intramural denizens with an interest in the science, technology, and in vivo application of magnetic resonance.

The group's mission is threefold: to encourage the use of MRI/MRS in biomedical applications, to promote interdisciplinary research and communication, and to disseminate information and provide consultative expertise.

The group intends to organize a seminar series and develop yellow pages of NIH groups involved in MRI research, a listserver with e-mail addresses of members, a calendar of events, and other vehicles for connecting people with similar research interests. They already have a web site: <http://www-mrips.cc.nih.gov/MRI>.

Meeting time: Alternate Wednesdays at 1:30 pm

For more info or to present your work during a Wednesday meeting, contact Jeff Duyn at
<jhd@helix.nih.gov>.


 


 

Cell Processing Facility Debuts

(Harvey Klein, Elizabeth Read)

On July 1, 1997, Harvey Klein (left), the Clinical Center's transfusion medicine chief, ushered in the new 3,000-square-foot cell-processing facility, created to isolate cellular components needed for intramural clinical trials, including hematopoietic progenitor cells, mononuclear cells, and other subsets of lymphocytes typically used in immunotherapy, gene therapy, and stem cell transplantion research. The facility is funded by the Clinical Center and Baxter Healthcare through a CRADA. Potential users of the service should contact Elizabeth Read (right), chief of the cell processing section.


 


 

CYTOKINE INTEREST GROUP SYMPOSIUM 
Thursday, December 11, 1997

DEFINING CYTOKINE BIOLOGY THROUGH
KNOCKOUT AND TRANSGENIC MOUSE MODELS

co-chaired by Jeff Green and John Letterio
The Laboratory of Chemoprevention, NCI

8:50-9:00 Welcome/Opening Remarks: Jeff Green/John Letterio

Approaches to the Study of Cytokines Through Gene Manipulation

9:00-9:30 Reprogramming the Mouse by Directed Genome Manipulation: B. Sauer, NIDDK

9:30-10:00 Dominant Negative Approaches to Define Cytokine Function in Development and Oncogenesis: Glenn Merlino, NCI

10:00-10:30 Distinct Developmental Defects Associated with Disruption of FGF-Receptors: Chuxia Deng, NIDDK

10:30-11:00 coffee break (vendor displays in foyer outside auditorium)

11:00-12:00 Studies of TGF-b Superfamily Function Through Knockouts of Ligands, Receptors, and Interacting Proteins: Martin Matzuk, Baylor College of Medicine

12:00 lunch (catered)

Gene Knockout Models in the Study of Immune Function

1:00-1:25 Experimental Autoimmune Uveitis and Protective Oral Tolerance in Cytokine Knockout Mice: Luiz Rizzo, NEI

1:25-1:50 Single, Double, and Triple Gene Targeting at the TNF/LT Locus Using the Cre-loxP Recombination System: Sergei Nedospasov, NCI, Frederick

1:50-2:15 Cytokine Knockouts Define Mechanisms of Host Resistance to Intracellular Infection: George Yap, NIAID

2:15-2:40 TGF-b1-/- Mice Reveal a Link Between Expression of the cdk Inhibitor p21cip1 and Lymphocyte Survival: John Letterio, NCI

2:40-3:05 Evaluation of Lymphocyte Development in TCR Zeta Chain Null Mice: Paul Love, NICHD

3:05-3:30 The Role of Innate and Adaptive Immune Responses in Experimental Autoimmunity Defined Through Studies in Cytokine Knockouts: Ben Segal, NIAID

3:30 Concluding Remarks: John Letterio/Jeff Green

3:45-5:00 refreshments / discussion / poster session in the atrium




Return to the Table of Contents